Philip Lecane

1.7k total citations
22 papers, 1.5k citations indexed

About

Philip Lecane is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Philip Lecane has authored 22 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 6 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Philip Lecane's work include Cancer-related Molecular Pathways (5 papers), Virus-based gene therapy research (4 papers) and Cancer Research and Treatments (4 papers). Philip Lecane is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), Virus-based gene therapy research (4 papers) and Cancer Research and Treatments (4 papers). Philip Lecane collaborates with scholars based in United States and United Kingdom. Philip Lecane's co-authors include Susan J. Knox, Jeffrey S. Armstrong, Ester M. Hammond, Geoffrey W. Birrell, Jonathan M. Irish, D M Peehl, Donna M. Peehl, Robert G. Sellers, Darren Magda and Richard A. Miller and has published in prestigious journals such as Blood, Molecular and Cellular Biology and Cancer Research.

In The Last Decade

Philip Lecane

22 papers receiving 1.4k citations

Peers

Philip Lecane

ONCOL

PRM

Lakshmipathi Khandrika United States

Jingjing Ma China

Amit Deorukhkar United States

Dennis Carney Australia

Wen‐Wei Qiu China

Xianhua Cao United States

Simran S. Sabharwal United States

Xiangming Guan United States

Changzheng Li China

Manu Lopus India

Lakshmipathi Khandrika United States

Philip Lecane

719 ×0.8

190 ×0.6

ONCOL

301 ×1.3

68 ×0.5

189 ×1.5

PRM

Citations per year, relative to Philip Lecane Philip Lecane (= 1×) peers Lakshmipathi Khandrika

Countries citing papers authored by Philip Lecane

Since Specialization

Citations

This map shows the geographic impact of Philip Lecane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Lecane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Lecane more than expected).

Fields of papers citing papers by Philip Lecane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Lecane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Lecane. The network helps show where Philip Lecane may publish in the future.

Co-authorship network of co-authors of Philip Lecane

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Lecane. A scholar is included among the top collaborators of Philip Lecane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Lecane. Philip Lecane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Olcina, Monica M., Philip Lecane, & Ester M. Hammond. (2010). Targeting Hypoxic Cells through the DNA Damage Response. Clinical Cancer Research. 16(23). 5624–5629. 94 indexed citations

Lin, Thomas S., Louie Naumovski, Philip Lecane, et al.. (2009). Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 50(12). 1977–1982. 16 indexed citations

Magda, Darren, Philip Lecane, Zhong Wang, et al.. (2008). Synthesis and Anticancer Properties of Water-Soluble Zinc Ionophores. Cancer Research. 68(13). 5318–5325. 76 indexed citations

Magda, Darren, Philip Lecane, Julia E. Prescott, et al.. (2008). mtDNA depletion confers specific gene expression profiles in human cells grown in culture and in xenograft. BMC Genomics. 9(1). 521–521. 41 indexed citations

Bencokova, Zuzana, et al.. (2008). ATM Activation and Signaling under Hypoxic Conditions. Molecular and Cellular Biology. 29(2). 526–537. 168 indexed citations

Wang, Zhong, Philip Lecane, Qing Fan, et al.. (2007). Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expression. Molecular Cancer. 6(1). 9–9. 29 indexed citations

Naumovski, Louie, Mint Sirisawad, Philip Lecane, et al.. (2006). Tumor localization and antitumor efficacy of novel sapphyrin compounds. Molecular Cancer Therapeutics. 5(11). 2798–2805. 18 indexed citations

Magda, Darren, Philip Lecane, Richard A. Miller, et al.. (2005). Motexafin Gadolinium Disrupts Zinc Metabolism in Human Cancer Cell Lines. Cancer Research. 65(9). 3837–3845. 53 indexed citations

Naumovski, Louie, Jason Ramos, Mint Sirisawad, et al.. (2005). Sapphyrins induce apoptosis in hematopoietic tumor–derived cell lines and show in vivo antitumor activity. Molecular Cancer Therapeutics. 4(6). 968–976. 35 indexed citations

10.

Evens, Andrew M., Philip Lecane, Darren Magda, et al.. (2004). Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood. 105(3). 1265–1273. 71 indexed citations

11.

Magda, Darren, et al.. (2004). Motexafin Gadolinium Mobilizes Zinc and Inhibits Thioredoxin Reductase in Human Lymphoma Cell Lines.. Blood. 104(11). 4316–4316. 1 indexed citations

12.

Lecane, Philip, et al.. (2003). Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. The Prostate. 54(4). 258–267. 31 indexed citations

13.

Armstrong, Jeffrey S., Jonathan M. Irish, Philip Lecane, et al.. (2002). Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death and Differentiation. 9(3). 252–263. 431 indexed citations

14.

Magda, Darren, Nikolay Gerasimchuk, Philip Lecane, et al.. (2002). Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chemical Communications. 2730–2731. 41 indexed citations

15.

Lecane, Philip, et al.. (2002). Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells.. PubMed. 8(8). 2666–74. 160 indexed citations

16.

Armstrong, Jeffrey S., et al.. (2001). Rotenone-Induced G2/M Cell Cycle Arrest and Apoptosis in a Human B Lymphoma Cell Line PW. Biochemical and Biophysical Research Communications. 289(5). 973–978. 71 indexed citations

17.

Gallimore, P. H., Philip Lecane, Byron Hann, & Roger J.A. Grand. (1997). Differentiation is inhibited and a senescence pathway is activated when simian virus 40 tsA 58-transformed human retinoblasts are grown at the restrictive temperature.. PubMed. 8(7). 763–71. 6 indexed citations

18.

Gallimore, P. H., Philip Lecane, Sally Roberts, et al.. (1997). Adenovirus type 12 early region 1B 54K protein significantly extends the life span of normal mammalian cells in culture. Journal of Virology. 71(9). 6629–6640. 19 indexed citations

19.

Grand, Roger J.A., Philip Lecane, Darerca Owen, et al.. (1995). The High Levels of p53 Present in Adenovirus Early Region 1-Transformed Human Cells do Not Cause Up-Regulation of MDM2 Expression. Virology. 210(2). 323–334. 23 indexed citations

20.

Grand, Roger J.A., Philip Lecane, Sally Roberts, et al.. (1993). Overexpression of Wild-Type p53 and c-Myc in Human Fetal Cells Transformed with Adenovirus Early Region 1. Virology. 193(2). 579–591. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact